{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:01:45Z","timestamp":1785013305040,"version":"3.55.0"},"reference-count":129,"publisher":"Begell House","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Oncog"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Neurotransmitters are critical signaling molecules of the nervous system that activate their receptors within milliseconds, and convey accurate, coordinated, tightly regulated and important messages from one nerve cell, across a synapse, to another nerve, muscle or gland cell. It is time to realize that specific neurotransmitters also activate T cells directly and rapidly via their receptors in T cells. Subsequently, they decrease immune checkpoint inhibitors, increase expression of critical receptors, and induce a kaleidoscope of effector T cell functions. This review summarizes our discoveries of direct, activating, rejuvenating, and strengthening effects of either Dopamine, Glutamate, GnRH-II or Neuropeptide Y, or their combinations on human T cells of five origins: (1) normal T cells of healthy people, (2) exhausted T cells of head and neck cancer patients, (3) exhausted T cells of hepatocellular carcinoma patients, (4) exhausted T cells of glioblastoma patients, and (5) human genetically-engineered CAR T cells. The beneficial effects of these neurotransmitters on healthy T cells and on exhausted T cells of cancer patients include the following: depolarization; simultaneous decreased expression of key checkpoint inhibitors (PD-1, LAG-3, Tim-3, TIGIT and CD160); increased expression of CD3 zeta chain, CD147\/EMM-PRIN\/Basigin and 67kDa laminin receptor; and increased adhesion to fibronectin and laminin, chemotactic migration to SDF-1, migration toward autologous tumors, gene expression, cytokine secretion, proliferation, and arrest of human cancer cells. The direct effects of GnRH-II, Dopamine, or Glutamate on human anti-breast cancer ErbB-2&lt;sup&gt;+&lt;\/sup&gt;\nCAR T cells were discovered in a yet unpublished collaborative research with Professor Zelig Eshhar, the pioneering scientist who invented and developed the concept of T-bodies, later re-named CAR T cells. The direct effects of the neurotransmitters on these CAR T cells include (1) dramatically increased expression of: CD3 zeta, CD147 and CXCR4, within only 30 minutes; (2) increased chemotactic migration towards SDF-1; (3) increased migration toward breast cancer cells; (4) increased penetration of the bone marrow of SCID mice; (5) increased homing to human breast cancer in SCID mice; and (6) increased inhibition of human breast cancer in SCID mice. In summary, either Glutamate, Dopamine, Neuropeptide Y, GnRH-II or their combinations, can activate, rescue, and strengthen healthy, exhausted, and genetically engineered CAR T cells. A novel personalized adoptive immunotherapy, called Brain-iT Immunotherapy, was invented and patented, and the review details its diagnostic and therapeutic stages for either patient's exhausted T cells or genetically engineered CAR T cells.<\/p>","DOI":"10.1615\/critrevoncog.2026064153","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T20:18:38Z","timestamp":1775765918000},"page":"67-107","source":"Crossref","is-referenced-by-count":0,"title":["Brain-iT Immunotherapy: The Neurotransmitters Dopamine, Glutamate, GnRH-II and Neuropeptide Y Revive, Activate and Empower Healthy T Cells, Exhausted T Cells of Cancer Patients, and Genetically Engineered CAR T Cells"],"prefix":"10.1615","volume":"31","author":[{"given":"Mia","family":"Levite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Levite M. Nerve-Driven Immunity: Neurotransmitters and Neuropeptides in the immune system. Vienna, Austria: Springer; 2012. p. 359.","DOI":"10.1007\/978-3-7091-0888-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Levite M. Nerve-Driven Immunity. The direct effects of Neurotransmitters on T-cell function. Ann N Y Acad Sci. 2000;917:307-\u0080\u009321.","DOI":"10.1111\/j.1749-6632.2000.tb05397.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Levite M. Dopamine in the immune system: Dopamine receptors in immune cells, potent effects, endogenous production and involvement in immune and neuropsychiatric diseases. In: Nerve Driven Immunity: Neurotransmitters and Neuropeptides in the immune system. Vienna, Austria: Springer; 2012. p. 1-\u0080\u009345.","DOI":"10.1007\/978-3-7091-0888-8_1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Levite M. Dopamine and T cells: Dopamine receptors and potent effects on T cells, Dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol. 2016;216(1):42-\u0080\u009389.","DOI":"10.1111\/apha.12476"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Ganor Y, Levite M. Glutamate in the immune system: Glutamate receptors in immune cells, potent effects, endogenous production and involvement in disease. In: Levite M, editor. Nerve-driven immunity: Neurotransmitters and neuropeptides in the immune system. Vienna, Austria: Springer; 2012. p. 121-\u0080\u009361.","DOI":"10.1007\/978-3-7091-0888-8_4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Ganor Y, Levite M. The Neurotransmitter Glutamate and human T cells: Glutamate receptors and Glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells. J Neural Transm. 2014;121(8):983-\u0080\u00931006.","DOI":"10.1007\/s00702-014-1167-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Levite M. T cells plead for rejuvenation and amplification; with the brain's Neurotransmitters and Neuropeptides we can make it happen. Front Immunol. 2021;12:617658. doi: 10.3389\/fimmu.2021.617658.","DOI":"10.3389\/fimmu.2021.617658"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Levite M, Safadi R, Milgrom Y, Massarwa M, Galun E. Neurotransmitters and Neuropeptides decrease PD-1 in T cells of healthy subjects and patients with hepatocellular carcinoma (HCC), and increase their proliferation and eradication of HCC cells. Neuropeptides. 2021;89:102159.","DOI":"10.1016\/j.npep.2021.102159"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Keren A, Gilhar A, Ullmann Y, Zlotkin-Fru\u0161i\u0107 M, Soroka Y, Domb AJ, Levite M. Instantaneous depolarization of T cells via Dopamine receptors, and inhibition of activated T cells of psoriasis patients and inflamed human skin, by D1-like receptor agonist: Fenoldopam. Immunology. 2019;158(3):171-\u0080\u009393.","DOI":"10.1111\/imm.13109"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3 or D1\/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J Neuroimmunol. 2005;169(1-2):161-\u0080\u009371.","DOI":"10.1016\/j.jneuroim.2005.07.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Levite M, Chowers Y, Ganor Y, Besser M, Hershkovits R, Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur J Immunol. 2001;31(12):3504-\u0080\u009312.","DOI":"10.1002\/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F"},{"key":"12","unstructured":"Levite M. Dopamine and T cells: Receptors, direct and potent effects, endogenous production and abnormalities in autoimmune, neurological and psychiatric diseases. Acta Physiol. 2015;10."},{"key":"13","doi-asserted-by":"crossref","unstructured":"Saussez S, Laumbacher B, Chantrain G, Rodriguez A, Gu S, Wank R, Levite M. Towards neuroimmunotherapy for cancer: The Neurotransmitters Glutamate, Dopamine and GnRH-II augment substantially the ability of T cells of few head and neck cancer patients to perform spontaneous migration, chemotactic migration and migration towards the autologous tumor, and also elevate markedly the expression of CD3zeta and CD3epsilon TCR-associated chains. J Neural Transm. 2014 Aug;121(8):1007-\u0080\u009327.","DOI":"10.1007\/s00702-014-1242-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Levite M, Ilouz N, Galun, E., Shoshan Y. Empowering exhausted T cells of Glioblastoma patients by Neurotransmitters and Neuropeptides: Decreasing immune checkpoint inhibitors, and increasing CD3zeta, proliferation and Glioblastoma arrest. Cancer Immunol Immunother. 2026;75(2):54.","DOI":"10.1007\/s00262-025-04226-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M. Human T cells express a functional ionotropic Glutamate receptor GluR3, and Glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J Immunol. 2003;170(8):4362-\u0080\u009372.","DOI":"10.4049\/jimmunol.170.8.4362"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y, Levite M. The Neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med. 2002;8(12):1421-\u0080\u00936.","DOI":"10.1038\/nm1202-801"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocrine Rev. 2005;26(2):283-\u0080\u0093306.","DOI":"10.1210\/er.2003-0039"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Desaulniers AT, Cederberg RA, Lents CA, White BR. Expression and role of gonadotropin-releasing hormone 2 and its receptor in mammals. Front Endocrinol. 2017;8:269.","DOI":"10.3389\/fendo.2017.00269"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Desaulniers AT, White BR. Role of gonadotropin-releasing hormone 2 and its receptor in human reproductive cancers. Front Endocrinol. 2023;14:1341162.","DOI":"10.3389\/fendo.2023.1341162"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Levite M, Cahalon L, Hershkoviz R, Steinman L, Lider O. Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin. J Immunol. 1998;160(2):993-\u0080\u00931000.","DOI":"10.4049\/jimmunol.160.2.993"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Levite M. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci U S A. 1998;95(21):12544-\u0080\u00939.","DOI":"10.1073\/pnas.95.21.12544"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Zhang B, Feng H, Lin H, Li R. Somatostatin-SSTR3-GSK3 modulates human T-cell responses by inhibiting OXPHOS. Front Immunol. 2024;15:1322670.","DOI":"10.3389\/fimmu.2024.1322670"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Petrovic-Dergovic DM, Rakin AK, Dimitrijevic LA, Ristovski JS, Kustrimovic NZ, Micic MV. Changes in thymus size, cellularity and relation between thymocyte subpopulations in young adult rats induced by somatostatin-14. Neuropeptides. 2007;41(6):485-\u0080\u009393.","DOI":"10.1016\/j.npep.2007.06.003"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Petrovic-Djergovic DM, Rakin AK, Kustrimovic NZ, Ristovski JS, Dimitrijevic LA, Mileva MV. Somatostatin modulates T cells development in adult rat thymus. Regul Peptides. 2007;142(3):101-\u0080\u009310.","DOI":"10.1016\/j.regpep.2007.02.003"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Santambrogio L, Lipartiti M, Bruni A, Dal Toso R. Dopamine receptors on human T- and B-lymphocytes. J Neuroimmunol. 1993;45(1-2):113-\u0080\u00939.","DOI":"10.1016\/0165-5728(93)90170-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, Moots RJ. Dopamine receptor expression on human T-and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: A flow cytometric study. J Neuroimmunol. 2002;132(1-2):34-\u0080\u009340.","DOI":"10.1016\/S0165-5728(02)00280-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Ilani T, Strous RD, Fuchs S. Dopaminergic regulation of immune cells via D3 Dopamine receptor: A pathway mediated by activated T cells. FASEB J. 2004;18(13):1600-\u0080\u00932.","DOI":"10.1096\/fj.04-1652fje"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Levite M, Marino F, Cosentino M. Dopamine, T cells and multiple sclerosis (MS). J Neural Transm. 2017;124(5):525-\u0080\u009342.","DOI":"10.1007\/s00702-016-1640-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Kustrimovic N, Rasini E, Legnaro M, Marino F, Cosentino M. Expression of dopaminergic receptors on human CD4+ T lymphocytes: Flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease. J Neuroimmune Pharmacol. 2014;9(3):302-\u0080\u009312.","DOI":"10.1007\/s11481-014-9541-5"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Lombardi G, Dianzani C, Miglio G, Canonico PL, Fantozzi R. Characterization of ionotropic Glutamate receptors in human lymphocytes. Br J Pharmacol. 2001;133(6):936-\u0080\u009344.","DOI":"10.1038\/sj.bjp.0704134"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Levite M. Glutamate, T cells and multiple sclerosis. J Neural Transm. 2017;124(7):775-\u0080\u009398.","DOI":"10.1007\/s00702-016-1661-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Pacheco R, Gallart T, Lluis C, Franco R. Role of Glutamate on T-cell mediated immunity. J Neuroimmunol. 2007;185(1-2):9-\u0080\u009319.","DOI":"10.1016\/j.jneuroim.2007.01.003"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Scicchitano R, Stanisz AM, Payan DG, Kiyono H, McGhee JR, Bienenstock J. Expression of substance P and somatostatin receptors on a T helper cell line. Adv Exp Med Biol. 1987;216A:185-\u0080\u009390.","DOI":"10.1007\/978-1-4684-5344-7_21"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Ferone D, Kwekkeboom DJ, Pivonello R, Bogers AD, Colao A, Lamberts SW, Van Hagen PM, Hofland LJ. In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. J Endocrinol Invest. 2001;24(7):522-\u0080\u00938.","DOI":"10.1007\/BF03343886"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Ferone D, Pivonello R, Van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, Van Koetsveld PM, Mooy DM, Colao A, Minuto F, Lamberts SW. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab. 2002;283(5):E1056-\u0080\u009366.","DOI":"10.1152\/ajpendo.00205.2001"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Ferone D, van Hagen MP, Kwekkeboom DJ, van Koetsveld PM, Mooy DM, Lichtenauer-Kaligis E, Scho\u00cc\u0088nbrunn A, Colao A, Lamberts SW, Hofland LJ. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab. 2000;85(4):1719-\u0080\u009326.","DOI":"10.1210\/jcem.85.4.6547"},{"key":"37","unstructured":"Ferone D, van Hagen PM, Colao A, Annunziato L, Lamberts SW, Hofland LJ. Somatostatin receptors in the thymus. Ann Med. 1999;31(Suppl 2):28-\u0080\u009333."},{"key":"38","doi-asserted-by":"crossref","unstructured":"Ferone D, Van Hagen PM, Semino C, Dalm VA, Barreca A, Colao A, Lamberts SW, Minuto F, Hofland LJ. Somatostatin receptor distribution and function in immune system. Digest Liver Dis. 2004;36:S68-\u0080\u009377.","DOI":"10.1016\/j.dld.2003.11.020"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy DM, Lichtenauer-Kaligis EG, Colao A, Bogers AJ, Lombardi G, Lamberts SW, Hofland LJ. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology. 1999;140(1): 373-\u0080\u009380.","DOI":"10.1210\/endo.140.1.6398"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Ghamrawy CE, Rabourdin-Combe C, Krantic S. sst5 somatostatin receptor mRNA induction by mitogenic activation of human T-lymphocytes. Peptides. 1999;20(3):305-\u0080\u009311.","DOI":"10.1016\/S0196-9781(99)00036-4"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Talme T, Liu Z, Sundqvist KG. The Neuropeptide calcitonin gene-related peptide (CGRP) stimulates T cell migration into collagen matrices. J Neuroimmunol. 2008;196(1-2):60-\u0080\u00936.","DOI":"10.1016\/j.jneuroim.2008.02.007"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Granstein RD, Wagner JA, Stohl LL, Ding W. Calcitonin gene-related peptide: Key regulator of cutaneous immunity. Acta Physiol. 2015;213(3):586-\u0080\u009394.","DOI":"10.1111\/apha.12442"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Teresi S, Boudard F, Bastide M. Effect of calcitonin gene-related peptide and vasoactive intestinal peptide on murine CD4 and CD8 T cell proliferation. Immunol Lett. 1996;50(1-2):105-\u0080\u009313.","DOI":"10.1016\/0165-2478(96)02524-2"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Umeda Y, Arisawa M. Characterization of the calcitonin gene-related peptide receptor in mouse T lymphocytes. Neuropeptides. 1989;14(4):237-\u0080\u009342.","DOI":"10.1016\/0143-4179(89)90052-8"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Wang H, Xing L, Li W, Hou L, Guo J, Wang X. Production and secretion of calcitonin gene-related peptide from human lymphocytes. J Neuroimmunol. 2002;130(1-2): 155-\u0080\u009362.","DOI":"10.1016\/S0165-5728(02)00221-7"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Chen HF, Jeung EB, Stephenson M, Leung PC. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. The J Clin Endocrinol Metab. 1999;84(2):743-\u0080\u009350.","DOI":"10.1210\/jc.84.2.743"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux PM. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol. 2005;142(1):103-\u0080\u009310.","DOI":"10.1111\/j.1365-2249.2005.02904.x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Tanriverdi F, Gonzalez-Martinez D, Silveira LF, Hu Y, Maccoll GS, Travers P, Bouloux PM. Expression of gonadotropin-releasing hormone type-I (GnRH-I) and type-II (GnRH-II) in human peripheral blood mononuclear cells (PMBCs) and regulation of B-lymphoblastoid cell proliferation by GnRH-I and GnRH-II. Exp Clin Endocrinol Diabetes. 2004;112(10):587-\u0080\u009394.","DOI":"10.1055\/s-2004-830404"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Jacobson JD, Crofford LJ, Sun L, Wilder RL. Cyclical expression of GnRH and GnRH receptor mRNA in lymphoid organs. Neuroendocrinology. 1998;67(2):117-\u0080\u009325.","DOI":"10.1159\/000054306"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Wang X, Zhong L, Liu Q, Cai P, Zhang P, Lu Z, Li X, Liu J. Activation of gonadotropin-releasing hormone receptor impedes the immunosuppressive activity of decidual regulatory T cells via deactivating the mechanistic target of rapamycin signaling. Immunol Invest. 2022;51(5):1330-\u0080\u009346.","DOI":"10.1080\/08820139.2021.1937208"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Levite M, Cahalon L, Peretz A, Hershkoviz R, Sobko A, Ariel A, Desai R, Attali B, Lider O. Extracellular K+ and opening of voltage-gated potassium channels activate T cell integrin function: Physical and functional association between Kv1. 3 channels and \u00ce\u00b21 integrins. J Exp Med. 2000;191(7):1167-\u0080\u009376.","DOI":"10.1084\/jem.191.7.1167"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Mouw JK, Ou G, Weaver VM. Extracellular matrix assembly: A multiscale deconstruction. Nat Rev Mol Cell Biol. 2014;15(12):771-\u0080\u009385.","DOI":"10.1038\/nrm3902"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Xu C, Xu XZ, Nunemaker CS, Moenter SM. Dose-dependent switch in response of gonadotropin-releasing hormone (GnRH) neurons to GnRH mediated through the type I GnRH receptor. Endocrinology. 2004;145(2):728-\u0080\u009335.","DOI":"10.1210\/en.2003-0562"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Krsmanovic LZ, Mores N, Navarro CE, Arora KK, Catt KJ. An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile Neuropeptide secretion. Proc Natl Acad Sci U S A. 2003;100(5):2969-\u0080\u009374.","DOI":"10.1073\/pnas.0535708100"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Chen P, Moenter SM. GABAergic transmission to gonadotropin-releasing hormone (GnRH) neurons is regulated by GnRH in a concentration-dependent manner engaging multiple signaling pathways. J Neurosci. 2009;29(31):9809-\u0080\u009318.","DOI":"10.1523\/JNEUROSCI.2509-09.2009"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Canfield SM, Khakoo AY. The nonintegrin laminin binding protein (p67 LBP) is expressed on a subset of activated human T lymphocytes and, together with the integrin very late activation antigen-6, mediates avid cellular adherence to laminin. J Immunol. 1999;163(6):3430-\u0080\u009340.","DOI":"10.4049\/jimmunol.163.6.3430"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Aboaid H, Khalid T, Hussain A, Myat YM, Nanda RK, Srinivasmurthy R, Nguyen K, Jones DT, Bigcas JL, Thein KZ. Advances and challenges in immunotherapy in head and neck cancer. Front Immunol. 2025;16:1596583.","DOI":"10.3389\/fimmu.2025.1596583"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33(29):3293-\u0080\u0093304.","DOI":"10.1200\/JCO.2015.61.1509"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Moskovitz JM, Ferris RL. Tumor immunology and immunotherapy for head and neck squamous cell carcinoma. J Dent Res. 2018;97(6):622-\u0080\u00936.","DOI":"10.1177\/0022034518759464"},{"key":"60","unstructured":"Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res. 1999;5(2):329-\u0080\u009334."},{"key":"61","unstructured":"Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998;58(23):5344-\u0080\u00937."},{"key":"62","doi-asserted-by":"crossref","unstructured":"Whiteside TL. Down-regulation of zeta-chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol Immunother. 2004;53(10):865-\u0080\u009378.","DOI":"10.1007\/s00262-004-0521-0"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev. 2005;24(1):95-\u0080\u0093105.","DOI":"10.1007\/s10555-005-5050-6"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Boniface JD, Poschke I, Mao Y, Kiessling R. Tumor-dependent down-regulation of the zeta-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer. 2012;131(1):129-\u0080\u009339.","DOI":"10.1002\/ijc.26355"},{"key":"65","unstructured":"Gruber IV, El Yousfi S, Durr-Storzer S, Wallwiener D, Solomayer EF, Fehm T. Down-regulation of CD28, TCRzeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res. 2008;28(2A):779-\u0080\u009384."},{"key":"66","doi-asserted-by":"crossref","unstructured":"Maccalli C, Pisarra P, Vegetti C, Sensi M, Parmiani G, Anichini A. Differential loss of T cell signaling molecules in metastatic melanoma patients-\u0080\u0099 T lymphocyte subsets expressing distinct TCR variable regions. J Immunol. 1999;163(12):6912-\u0080\u009323.","DOI":"10.4049\/jimmunol.163.12.6912"},{"key":"67","unstructured":"Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'\u0080\u0099Shea JJ, Powers GC, Urba WJ. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res. 1995;1(11):1327-\u0080\u009335."},{"key":"68","doi-asserted-by":"crossref","unstructured":"Farace F, Angevin E, Vanderplancke J, Escudier B, Triebel F. The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration. Int J Cancer. 1994;59(6):752-\u0080\u00935.","DOI":"10.1002\/ijc.2910590607"},{"key":"69","unstructured":"Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P, Kiessling R. Decreased expression of the signal-transducing \u00ce\u00b6 chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993;53(23):5610-\u0080\u00932."},{"key":"70","doi-asserted-by":"crossref","unstructured":"Frydecka I, Kaczmarek P, Bocko D, Kosmaczewska A, Morilla R, Catovsky D. Expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with Hodgkin's disease in different phases of the disease. Leuk Lymphoma. 1999;35(5-6): 545-\u0080\u009354.","DOI":"10.1080\/10428199909169619"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345-\u0080\u009362.","DOI":"10.1016\/S0140-6736(22)01200-4"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Eggert T, Greten TF. Tumor regulation of the tissue environment in the liver. Pharmacol Ther. 2017;173:47-\u0080\u009357.","DOI":"10.1016\/j.pharmthera.2017.02.005"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Galun E. Liver inflammation and cancer: The role of tissue microenvironment in generating the tumor-promoting niche (TPN) in the development of hepatocellular carcinoma. Hepatology. 2016;63(2):354-\u0080\u00936.","DOI":"10.1002\/hep.28344"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-\u00ce\u00baB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461-\u0080\u00936.6.","DOI":"10.1038\/nature02924"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Barashi N, Weiss ID, Wald O, Wald H, Beider K, Abraham M, Klein S, Goldenberg D, Axelrod J, Pikarsky E, Abramovitch R. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology. 2013;58(3):1021-\u0080\u009330.","DOI":"10.1002\/hep.26403"},{"key":"76","doi-asserted-by":"crossref","unstructured":"Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, El-Gindi M, Han M. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253-\u0080\u00937.","DOI":"10.1038\/nature16969"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50(3):799-\u0080\u0093807.","DOI":"10.1002\/hep.23054"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Hung MH, Lee JS, Ma C, Diggs LP, Heinrich S, Chang CW, Ma L, Forgues M, Budhu A, Chaisaingmongkol J, Ruchirawat M. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat Commun. 2021;12(1):1455.","DOI":"10.1038\/s41467-021-21804-1"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Cui Z, Li H, Liu C, Wang J, Chen C, Hu S, Zhao X, Li G. Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T cell subpopulations in hepatocellular carcinoma. Aging. 2024;16(7):6550.","DOI":"10.18632\/aging.205723"},{"key":"80","doi-asserted-by":"crossref","unstructured":"Li J, Chen H, Bai L, Tang H. Identification of CD8(+) T-cell exhaustion signatures for prognosis in HBV-related hepatocellular carcinoma patients by integrated analysis of single-cell and bulk RNA-sequencing. BMC Cancer. 2024;24(1):53.","DOI":"10.1186\/s12885-023-11804-3"},{"key":"81","doi-asserted-by":"crossref","unstructured":"Ma J, Zheng B, Goswami S, Meng L, Zhang D, Cao C, Li T, Zhu F, Ma L, Zhang Z, Zhang S. PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J Immunother Cancer. 2019;7(1):331.","DOI":"10.1186\/s40425-019-0814-7"},{"key":"82","doi-asserted-by":"crossref","unstructured":"Zhang G. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment. Front Immunol. 2022;13:975762.","DOI":"10.3389\/fimmu.2022.975762"},{"key":"83","unstructured":"Thermofisher. Cell concentration in human and mouse samples Available from: https:\/\/assets.thermofisher.com\/TFS-Assets\/LSG\/brochures\/I-076357%20cell%20count%20table%20topp_WEB.pdf."},{"key":"84","unstructured":"Stemcell Technologies. Frequencies of cell types in human peripheral blood. Available from: https:\/\/geiselmed.dartmouth.edu\/dartlab\/wp-content\/uploads\/sites\/22\/2017\/05\/CellTypes-StemCell.pdf."},{"key":"85","unstructured":"Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073-\u0080\u0093113."},{"key":"86","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: Current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21(12):1354-\u0080\u009375.","DOI":"10.1038\/s41423-024-01226-x"},{"key":"87","doi-asserted-by":"crossref","unstructured":"Agosti E, Zeppieri M, De Maria L, Tedeschi C, Fontanella MM, Panciani PP, Ius T. Glioblastoma immunotherapy: A systematic review of the present strategies and prospects for advancements. Int J Mol Sci. 2023;24(20): 15037.","DOI":"10.3390\/ijms242015037"},{"key":"88","doi-asserted-by":"crossref","unstructured":"Choi BD, Maus MV, June CH, Sampson JH. Immunotherapy for glioblastoma: Adoptive T-cell strategies. Clin Cancer Res. 2019;25(7):2042-\u0080\u00938.","DOI":"10.1158\/1078-0432.CCR-18-1625"},{"key":"89","doi-asserted-by":"crossref","unstructured":"Watowich MB, Gilbert MR, Larion M. T cell exhaustion in malignant gliomas. Trends Cancer. 2023;9(4):270-\u0080\u009392.","DOI":"10.1016\/j.trecan.2022.12.008"},{"key":"90","doi-asserted-by":"crossref","unstructured":"Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 2018;24(17):4175-\u0080\u009386.","DOI":"10.1158\/1078-0432.CCR-17-1846"},{"key":"91","doi-asserted-by":"crossref","unstructured":"Mohme M, Schliffke S, Maire CL, R\u00fcnger A, Glau L, Mende KC, Matschke J, Gehbauer C, Aky\u00fcz N, Zapf S, Holz M. Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-inf\u00ef\u00bb\u00bfi ltrating lymphocytes. Clin Cancer Res. 2018;24(17):4187-\u0080\u0093200.","DOI":"10.1158\/1078-0432.CCR-17-2617"},{"key":"92","doi-asserted-by":"crossref","unstructured":"Davidson TB, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki A. Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clin Cancer Res. 2019;25(6):1913-\u0080\u009322.","DOI":"10.1158\/1078-0432.CCR-18-1176"},{"key":"93","doi-asserted-by":"crossref","unstructured":"Woroniecka K, Fecci PE. T-cell exhaustion in glioblastoma. Oncotarget. 2018;9(82):35287-\u0080\u00938.","DOI":"10.18632\/oncotarget.26228"},{"key":"94","doi-asserted-by":"crossref","unstructured":"Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. T-cell dysfunction in glioblastoma: Applying a new framework. Clin Cancer Res. 2018;24(16): 3792-\u0080\u0093802.","DOI":"10.1158\/1078-0432.CCR-18-0047"},{"key":"95","doi-asserted-by":"crossref","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024-\u0080\u00938.","DOI":"10.1073\/pnas.86.24.10024"},{"key":"96","unstructured":"Gross G, Gorochov G, Waks T, Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc. 1989;21(1 Pt 1):127-\u0080\u009330."},{"key":"97","unstructured":"Eshhar Z, Gross G. Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: A model system for immunotherapeutical approach. Br J Cancer Suppl. 1990;10:27-\u0080\u00939."},{"key":"98","doi-asserted-by":"crossref","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720-\u0080\u00934.","DOI":"10.1073\/pnas.90.2.720"},{"key":"99","doi-asserted-by":"crossref","unstructured":"Eshhar Z. The T-body approach: Redirecting T cells with antibody specificity. Handb Exp Pharmacol. 2008(181): 329-\u0080\u009342.","DOI":"10.1007\/978-3-540-73259-4_14"},{"key":"100","unstructured":"Eshhar Z. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic. Curr Opin Mol Ther. 2010;12(1):55-\u0080\u009363."},{"key":"101","doi-asserted-by":"crossref","unstructured":"Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods. 2001;248(1-2):67-\u0080\u009376.","DOI":"10.1016\/S0022-1759(00)00343-4"},{"key":"102","doi-asserted-by":"crossref","unstructured":"Globerson Levin A, Rawet Slobodkin M, Waks T, Horn G, Ninio-Many L, Deshet Unger N, Ohayon Y, Suliman S, Cohen Y, Tartakovsky B, Naparstek E. Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity. Cancer Immunol Res. 2020;8(12):1485-\u0080\u009395.","DOI":"10.1158\/2326-6066.CIR-20-0118"},{"key":"103","doi-asserted-by":"crossref","unstructured":"Marcus A, Eshhar Z. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther. 2014;14(7):947-\u0080\u009354.","DOI":"10.1517\/14712598.2014.900540"},{"key":"104","doi-asserted-by":"crossref","unstructured":"Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol. 1993;151(11):6577-\u0080\u009382.","DOI":"10.4049\/jimmunol.151.11.6577"},{"key":"105","unstructured":"Melina V. Migratory patterns of genetically modified lymphocytes [PhD Thesis Supervised by Prof. Zelig Eshhar]. Weizmann Institute of Science, Rehovot, Israel; 2006."},{"key":"106","doi-asserted-by":"crossref","unstructured":"Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged Persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: Challenges and ways forward. Front Immunol. 2020;11:702.","DOI":"10.3389\/fimmu.2020.00702"},{"key":"107","doi-asserted-by":"crossref","unstructured":"Kobayashi N, Takata H, Yokota S, Takiguchi M. Down-regulation of CXCR4 expression on human CD8+ T cells during peripheral differentiation. Eur J Immunol. 2004;34(12):3370-\u0080\u00938.","DOI":"10.1002\/eji.200425587"},{"key":"108","doi-asserted-by":"crossref","unstructured":"Shu P, Guo F, Qin D, Zou L, Ma Q, Zhang B, Gao G, Chen Y, He X, Jiang M, Liu N. CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies. Signal Transduct Target Ther. 2026 Jan 28;11(1):38.","DOI":"10.1038\/s41392-025-02522-2"},{"key":"109","doi-asserted-by":"crossref","unstructured":"Watanabe N, Mo F, McKenna MK. Impact of manufacturing procedures on CAR T cell functionality. Front Immunol. 2022;13:876339.","DOI":"10.3389\/fimmu.2022.876339"},{"key":"110","doi-asserted-by":"crossref","unstructured":"Posey AD, Jr., Young RM, June CH. Future perspectives on engineered T cells for cancer. Trends Cancer. 2024;10(8):687-\u0080\u009395.","DOI":"10.1016\/j.trecan.2024.05.007"},{"key":"111","doi-asserted-by":"crossref","unstructured":"Delgoffe GM, Xu C, Mackall CL, Green MR, Gottschalk S, Speiser DE, Zehn D, Beavis PA. The role of exhaustion in CAR T cell therapy. Cancer Cell. 2021;39(7):885-\u0080\u00938.","DOI":"10.1016\/j.ccell.2021.06.012"},{"key":"112","doi-asserted-by":"crossref","unstructured":"Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol. 2022;10:1034257.","DOI":"10.3389\/fcell.2022.1034257"},{"key":"113","doi-asserted-by":"crossref","unstructured":"Kouro T, Himuro H, Sasada T. Exhaustion of CAR T cells: Potential causes and solutions. J Transl Med. 2022;20(1):239.","DOI":"10.1186\/s12967-022-03442-3"},{"key":"114","doi-asserted-by":"crossref","unstructured":"Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin\/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006;56(7):359-\u0080\u009367.","DOI":"10.1111\/j.1440-1827.2006.01972.x"},{"key":"115","doi-asserted-by":"crossref","unstructured":"Guindolet D, Gabison EE. Role of CD147 (EMMPRIN\/Basigin) in tissue remodeling. Anat Rec. 2020;303(6):1584-\u0080\u00939.","DOI":"10.1002\/ar.24089"},{"key":"116","doi-asserted-by":"crossref","unstructured":"Xiong L, Edwards CK, 3rd, Zhou L. The biological function and clinical utilization of CD147 in human diseases: A review of the current scientific literature. Int J Mol Sci. 2014;15(10):17411-\u0080\u009341.","DOI":"10.3390\/ijms151017411"},{"key":"117","doi-asserted-by":"crossref","unstructured":"Bianchi ME, Mezzapelle R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front Immunol. 2020;11:2109.","DOI":"10.3389\/fimmu.2020.02109"},{"key":"118","doi-asserted-by":"crossref","unstructured":"Nagasawa T. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med. 2014;92(5):433-\u0080\u00939.","DOI":"10.1007\/s00109-014-1123-8"},{"key":"119","doi-asserted-by":"crossref","unstructured":"Weihe E, Nohr D, Michel S, M\u00fcller S, Zentel HJ, Fink T, Krekel J. Molecular anatomy of the neuro-immune connection. Int J Neurosci. 1991;59(1-3):1-\u0080\u009323.","DOI":"10.3109\/00207459108985446"},{"key":"120","doi-asserted-by":"crossref","unstructured":"Felten DL, Overhage JM, Felten SY, Schmedtje JF. Noradrenergic sympathetic innervation of lymphoid tissue in the rabbit appendix: Further evidence for a link between the nervous and immune systems. Brain Res Bull. 1981;7(5):595-\u0080\u0093612.","DOI":"10.1016\/0361-9230(81)90010-1"},{"key":"121","doi-asserted-by":"crossref","unstructured":"Livnat S, Felten SY, Carlson SL, Bellinger DL, Felten DL. Involvement of peripheral and central catecholamine systems in neural-immune interactions. J Neuroimmunol. 1985;10(1):5-\u0080\u009330.","DOI":"10.1016\/0165-5728(85)90031-1"},{"key":"122","doi-asserted-by":"crossref","unstructured":"Felten DL, Felten SY, Bellinger DL, Carlson SL, Ackerman KD, Madden KS, Olschowki JA, Livnat S. Noradrenergic sympathetic neural interactions with the immune system: Structure and function. Immunol Rev. 1987;100(1):225-\u0080\u009360.","DOI":"10.1111\/j.1600-065X.1987.tb00534.x"},{"key":"123","doi-asserted-by":"crossref","unstructured":"Livnat S, Madden KS, Felten DL, Felten SY. Regulation of the immune system by sympathetic neural mechanisms. Prog Neuropsychopharmacol Biol Psych. 1987;11(2-3):145-\u0080\u009352.","DOI":"10.1016\/0278-5846(87)90052-2"},{"key":"124","doi-asserted-by":"crossref","unstructured":"Mignini F, Streccioni V, Amenta F. Autonomic innervation of immune organs and neuroimmune modulation. Auton Autacoid Pharmacol. 2003;23(1):1-\u0080\u009325.","DOI":"10.1046\/j.1474-8673.2003.00280.x"},{"key":"125","doi-asserted-by":"crossref","unstructured":"Nance DM, Sanders VM. Autonomic innervation and regulation of the immune system (1987-\u0080\u00932007). Brain Behav Immun. 2007;21(6):736-\u0080\u009345.","DOI":"10.1016\/j.bbi.2007.03.008"},{"key":"126","doi-asserted-by":"crossref","unstructured":"Madden KS, Sanders VM, Felten DL. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu Rev Pharmacol Toxicol. 1995;35:417-\u0080\u009348.","DOI":"10.1146\/annurev.pa.35.040195.002221"},{"key":"127","doi-asserted-by":"crossref","unstructured":"Madden KS, Rajan S, Bellinger DL, Felten SY, Felten DL. Age-associated alterations in sympathetic neural interactions with the immune system. Dev Comp Immunol. 1997;21(6):479-\u0080\u009386.","DOI":"10.1016\/S0145-305X(97)00028-1"},{"key":"128","doi-asserted-by":"crossref","unstructured":"ThyagaRajan S, Madden KS, Teruya B, Stevens SY, Felten DL, Bellinger DL. Age-associated alterations in sympathetic noradrenergic innervation of primary and secondary lymphoid organs in female Fischer 344 rats. J Neuroimmunol. 2011;233(1-2):54-\u0080\u009364.","DOI":"10.1016\/j.jneuroim.2010.11.012"},{"key":"129","unstructured":"Rea VE, Rossi FW, De Paulis A, Ragno P, Selleri C, Montuori N. 67 kDa laminin receptor: Structure, function and role in cancer and infection. Infez Med. 2012;20(Suppl 2):8-\u0080\u009312."}],"container-title":["Critical Reviews\u2122 in Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/39a5669e1139d9da\/CRO-64153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T20:35:07Z","timestamp":1785011707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/439f422d0783386a,5a518e4904bba712,39a5669e1139d9da.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevoncog.2026064153","relation":{},"ISSN":["0893-9675"],"issn-type":[{"value":"0893-9675","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}